MedTrace Logo

Safety and Effectiveness of Cartiva Implant in the Treatment of First CMC Joint Osteoarthritis Compared to LRTI (GRIP 2)

NCT03247439 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2020-12-03

No results posted yet for this study

Summary

This study will evaluate whether Cartiva is an effective treatment for individuals with osteoarthritis of the first CMC joint in the hand compared to LRTI.

Conditions

Interventions

DEVICE

Cartiva

Synthetic Cartilage Implant

Sponsors & Collaborators

  • Cartiva, Inc.

    lead INDUSTRY

Principal Investigators

  • Scott Wolfe, MD · Hospital for Special Surgery, New York

  • Christopher Bainbridge, MB ChB, FRCSEd, CCST · Royal Derby Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-22
Primary Completion
2020-10-30
Completion
2024-03-31
FDA Device
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03247439 on ClinicalTrials.gov